Compare iShares MSCI Australia ETF (EWA) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs GE HealthCare Technologies Inc. Common Stock — how do they compare? iShares MSCI Australia ETF trades at $28.55 (market cap $1.20B), while GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 25.9× iShares MSCI Australia ETF's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals.
| EWA | GEHC | |
|---|---|---|
Market Cap | $1.20B | $31.07B |
Volume | 1,742,887 | 3,443,020 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $88.16 |
52-Week Low | $24.95 | $59.48 |
Typical Hold Time | 61 Days | — |
Enterprise Value | — | $39.53B |
Dividend Yield | — | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.77, up 0.35% today, but technical indicators signal a bearish trend with moving averages and key oscillators like the 6-day RSI at 75.94 suggesting overbought conditions. The ETF tracks Australian equities, heavily weighted toward commodities and financials, with recent news highlighting institutional selling by Squarepoint Ops LLC amid broader market concerns over inflation and oil price volatility.
The outlook for EWA hinges on commodity demand and global economic trends, offering exposure to Australia's resource-driven economy but facing risks from inflation and geopolitical tensions. Analyst sentiment is mixed, with Seeking Alpha rating it a Buy targeting over 20% upside, while technical weakness and institutional selling pose near-term headwinds.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
